“The SSO2 Therapy system has the potential to provide interventional cardiologists with the first treatment option beyond angioplasty and stenting to save substantially more heart muscle in heart attack patients than the current state-of-the-art treatment,” said Kevin T. Larkin, president and CEO of TherOx. “The FDA’s acceptance for filing of our PMA brings us one step closer to providing a promising new tool to reduce infarct size and thus improve outcomes for heart attack patients, and we look forward to working with the FDA during the review process.”
Although percutaneous coronary intervention (PCI) is the standard of care in treating AMI, for many patients it doesn’t sufficiently reduce infarct size to achieve maximum clinical benefit. In SSO2 Therapy, the patient’s blood is supersaturated with oxygen and then returned directly to the targeted ischemic area of the heart through a small catheter. Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size.
The PMA application includes data from the IC-HOT (Evaluation of Intracoronary Hyperoxemic Oxygen Therapy) study, a confirmatory study that enrolled 100 patients at 15 investigational centers in the United States. The primary objective of the IC-HOT study was to collect confirmatory data supporting the safety and effectiveness of SSO2 Therapy in the treatment of anterior ST-elevation AMI patients who have undergone successful PCI with stenting within six hours of experiencing AMI symptoms.
SSO2 Therapy is intended to reduce infarct size by boosting oxygen delivery to the heart muscle immediately after the coronary artery has been opened by PCI. The TherOx SSO2 Therapy system delivers a one-time, 60-minute infusion of superoxygenated blood to the coronary arteries after standard-of-care treatment for heart attack has been completed. In the United States, SSO2 Therapy is delivered by an investigational device. It is limited by U.S. law to investigational use and is not for sale or distribution in the United States.
TherOx is a privately held medical device company based in Irvine, Calif., focused on developing and commercializing SSO2 Therapy for the AMI patient population.